Monday, August 07, 2017 10:34:10 AM
strong institutional support here:
MBRX:
Institutional holders:
Moleculin Biotech Inc, Inst Holders, 2Q 2017 (MBRX)
4:15 am ET July 20, 2017 (Dow Jones) Print
The following table shows the largest shareholders in MOLECULIN BIOTECH INC COM (MBRX) for the quarter ended June 30, 2017, listed by holding size. The list represents up to 50 of the largest holders in the company.
Institution Shares Shares % Last
Held Changed Held Report
The Vanguard Group Inc. 264,160 246,202 1.488 03/31
KCG Americas LLC 233,994 233,994 1.318 03/31
Sabby Capital LLC 100,000 100,000 0.563 03/31
Sterling Capital Management LL 40,000 20,000 0.225 03/31
Bank of America NA (Private B 25,000 0 0.141 03/31
Two Sigma Securities LLC 24,160 24,160 0.136 03/31
BlackRock Fund Advisors 17,868 0 0.101 03/31
Goldman Sachs & Co. LLC (Priva 17,509 17,509 0.099 03/31
Citadel Advisors LLC 17,304 17,304 0.097 03/31
Northern Trust Investments In 11,155 11,155 0.063 03/31
Morgan Stanley & Co. LLC 10,096 10,096 0.057 03/31
Wedbush Securities Inc. (Inve 10,000 10,000 0.056 03/31
UBS Securities LLC 4,537 2,415 0.026 03/31
Tower Research Capital LLC 3,100 2,900 0.017 03/31
Acrospire Investment Managemen 2,472 2,472 0.014 03/31
UBS Financial Services Inc. 2,000 2,000 0.011 03/31
Advocacy Wealth Management LLC 1,000 0 0.006 03/31
Morgan Stanley Smith Barney LL 700 0 0.004 03/31
NEXT Financial Group Inc. 500 500 0.003 06/30
WFG Advisors LP 400 0 0.002 03/31
Citigroup Global Markets Inc. 0 (7,500) 0.000 03/31
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
- Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
- Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/19/2024 02:06:59 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/16/2024 08:54:18 PM
- Moleculin Announces Pricing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:15 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 03:21:01 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 01:57:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:24 PM
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 01:05:10 PM
- Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET • PR Newswire (US) • 08/05/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:35:16 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM